At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Brivaracetam +1 moredrug
Likely dose
Brivaracetam 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Pilot Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Brivaracetam and Placebo for Spinal Cord Injuries. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course with brivarecetum.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartFeb 2021
Primary CompletionMar 2024
Study CompletionSep 2024
TodayJul 2026
First PostedMay 7, 2020
Enrollment StartFeb 1, 2021
Primary CompletionMar 31, 2024
Study CompletionSep 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.2 years ago
Interventions
Brivaracetamdrug
Escalating brivaracetam dose to 150 mg twice daily for 3 months
Placeboother
Placebo twice daily for 3 months